FDA Signals New Testosterone Pathway - Takeaway - MDSpire
FDA & Government News

FDA Signals New Testosterone Pathway

Agency invites sponsors to pursue low libido indication

Share

  • 1

    FDA encourages new TRT indications for low libido in idiopathic hypogonadism.

  • 2

    TRT currently approved for men with structural or genetic hypogonadism only.

  • 3

    Sponsors may submit supplemental applications by April

  • 4

    Substantial evidence of effectiveness and safety required for new indication.

  • 5

    Sexual health is deemed vital for quality of life.

Original Source(s)

FDA Signals New Testosterone Pathway

  • by Kathryn Wighton

  • April 16, 2026

Related Content

Mandatory Training Modules Deserve a Harder Look

A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.

Spectroscopy Roundup: Rover Dogs and Raman Vision

Semi-autonomous robots showcase the future of planetary exploration, as spectroscopy also reshapes lab-on-chip biology and microplastics research

  • April 14, 2026

  • 5 min
FDA Flags Missing Trial Results

Federal outreach seeks to improve compliance with ClinicalTrials.gov reporting requirements and make more complete clinical trial information publicly available